Additional examples are tumor necrosis factor-alpha (TNF-α) inhibitors and methotrexate used for treating autoimmune or inflammatory diseases, such as rheumatoid arthritis, psoriasis, or Crohn’s disease [2,3], and, importantly, the recently developed checkpoint inhibitors in cancer treatment often induce DIILD [4]. This evidence concerns the gene TNF and Crohn disease.